Mubadala Investment Company agreed to acquire €200 million (US$235 million) worth of Hamburg-based Evotec shares in a private placement, giving the United Arab Emirates sovereign wealth fund a 5.6% stake in one of Germany's top life sciences firms.
Novo Holdings kicked in an additional €50 million (US$58.8 million) in the offering. But Novo is a longtime Evotec investor that brought its stake in the company up to 11% with the transaction, so the headline news here is Mubadala's increasing eagerness to play the biotech trade.
Mubadala CEO Khaldoon . . .
Unlock this article instantly, along with the rest of our premium content, newsletters and data tables tracking investor and manager activity. Annual subscriptions get you the most bang for your buck, including access to Alternatives Watch Research articles and out Annual Investor Compendium.
Monthly subscriptions and discounted corporate plans for up to 100 members also available.